top of page

Brandon Adams

Analyst

Brandon serves as an Investment Analyst at Logos Capital.

 

Prior to Logos, Brandon was a Research Analyst at Point72 Asset Management, where he covered biotechnology and large cap pharma on a market neutral healthcare team. Prior to Point72, Brandon spent time as an analyst at a single manager biotech-focused hedge fund and in Piper Sandler’s Biopharma investment banking group. 

 

Brandon holds a B.S. in Biochemistry from Saint Mary’s College of California.

View LinkedIn

Brandon Adams

IR@logoscapital.com

+1 (415) 801-4660 or +1 (415) 801-4670

1 Letterman Drive, Building C, Suite C3-350, San Francisco, CA 94129

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Logos Global Management LP (“Logos Capital”). Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Logos Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Logos Capital were prepared based upon information, believed to be reliable, available to it at the time such views were written. Logos Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Logos Capital.

© 2025 Logos Capital

bottom of page